多中心真实世界数据评价药品安全性研究进展

doi:10.19803/j.1672-8629.20240016

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 703-708.
DOI: 10.19803/j.1672-8629.20240016

多中心真实世界数据评价药品安全性研究进展

汪春楠¹, 秦诗如^1△, 章萌^2,3, 宋海波⁴, 刘俊昌^5,6, 李戈^7#, 孙凤^2,3,5,*

¹天津中医药大学中药学院,天津 301617;
²北京大学公共卫生学院流行病与卫生统计学系,北京 100191;
³重大疾病流行病学教育部重点实验室（北京大学）,北京 100191;
⁴国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076;
⁵新疆医科大学,新疆 830017;
⁶新疆维吾尔自治区中医药研究院 830000;
⁷天津中医药大学公共卫生与健康科学学院,天津 301617

收稿日期:2024-01-11 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*孙凤,女,博士,研究员·博导,医学统计学与循证医学。E-mail：sunfeng@bjmu.edu.cn; ^#为共同通信作者。
作者简介:汪春楠,女,本科,临床药学。^△为并列第一作者。
基金资助:
国家自然科学基金资助项目（72361127500、82360979）; 中国药品监管科学行动计划第三批重点项目（RS2024Z008）; 新疆维吾尔自治区科技创新团队项目（2022TSYCTD0008）

Evaluation of drug safety with multicenter real-world data

WANG Chunnan¹, QIN Shiru^1△, ZHANG Meng^2,3, SONG Haibo⁴, LIU Junchang^5,6, LI Ge^7#, SUN Feng^2,3,5,*

¹School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;
²Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China;
³Key Laboratory of Epidemiology of Major Diseases (Peking University), Beijing 100191, China;
⁴Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China;
⁵Xinjiang Medical University, Xinjiang 830017, China;
⁶Xinjiang Uygur Autonomous Region Academy of Traditional Chinese Medicine, Urumqi Xinjiang 830000, China;
⁷School of Public Health of TJUTCM, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Received:2024-01-11 Online:2024-06-15 Published:2024-06-18

1. 多中心真实世界数据评价药品安全性研究进展.docx(262KB)

摘要/Abstract

摘要： 目的探讨基于多中心真实世界数据开展药品安全性评价的研究进展。方法检索并筛选有关文献,利用文献计量学工具Bibliometrix实现可视化分析,展示文献分布及关键词词频、共现、历时变化情况;提取并分析目标疾病及干预药物、真实世界数据来源、多中心数据共享情况等信息。结果纳入405篇文献,发文量逐年增长,研究重点关注肿瘤治疗中的药物干预,如靶向药、化疗药、糖皮质激素、免疫药物等,及循环系统疾病中口服抗凝药和抗血小板药等。作者关键词共现网络中有10个聚类,最主要的2个聚类中心为安全性和心房颤动。最常见数据来源是注册登记数据（217/405,53.5%）。当前以国家内部多个研究中心共享数据为主,欧洲实现了国家间数据共享。结论基于多中心真实世界数据评估药品安全研究热度不断增加,研究领域逐步扩大,涉及多种常见慢性病。构建国际性的多中心数据管理平台,共用真实世界多来源数据评估药品安全是未来研究和发展方向。

关键词: 药品安全, 药物警戒, 真实世界数据, 文献计量学, Bibliometrix, 多中心

Abstract: Objective To explore the progress, hot spots, and developments of research on drug safety evaluation based on multicenter real-world data. Methods PubMed, Web of Science, and Scopus were searched for literature on drug safety evaluation using multicenter real-world data. Firstly, bibliometrix was used for visual analysis of the time the included literature was published and the distribution of countries and journals. In addition, the frequency, co-occurrence, and diachronic changes of keywords were displayed. Information on the target diseases, intervention drugs, research safety outcomes, real-world data sources, multicenter data sharing was retrieved. Results A total of 405 publications in 2004-2023 were included in the analysis, and the number of publications increased year by year. Research focused on pharmacological interventions in neoplasms treatment, including targeted drugs, chemotherapeutic drugs, glucocorticoids, immunological agents, oral anticoagulants and antiplatelet drugs for circulatory disorders. The keyword co-occurrence analysis found 10 keyword clusters, the top two of which involved safety and atrial fibrillation. The most important source of data was the registry (217/405, 53.5%) in these studies. Currently, most research centers shared data within the country, so research data mostly came from more than 10 institutions (158/280, 56.4%). Data was shared across countries in Europe in this field. Conclusion There is increasing research on drug safety evaluation based on multicenter real-world data. The related research covers a wide range, such as neoplasms and circulatory system diseases. Multicenter data sharing between countries is increasing. Advances in information technology can facilitate inter-country RWD information exchange. The more commonly used real-world data is registry data and hospital database information. Building a global and multicenter data management platform and sharing real-world multi-source data will catch on.

Key words: drug safety, pharmacovigilance, real-world data, bibliometrics, Bibliometrix, multicenter

中图分类号:

R954
R994.11

汪春楠, 秦诗如, 章萌, 宋海波, 刘俊昌, 李戈, 孙凤. 多中心真实世界数据评价药品安全性研究进展[J]. 中国药物警戒, 2024, 21(6): 703-708.

WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng. Evaluation of drug safety with multicenter real-world data[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20240016

https://www.zgywjj.com/CN/Y2024/V21/I6/703

参考文献

[1] SHANG PH, LIU J, XIA YY, et al.A systematic review and qualitative analysis of the definition and scope of drug safety in China[J]. Chinese Journal of Health Policy(中国卫生政策研究), 2009, 2(6): 39-44.
[2] LAVERTU A, VORA B, GIACOMINI KM, et al.A new era in pharmacovigilance: toward real-world data and digital monitoring[J]. Clin Pharmacol Ther, 2021, 109(5): 1197-1202.
[3] MENG RG, ZHUO L, QIAO R, et al.Application values of real-world evidence in post-marketing surveillances and evaluation for drug safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(7): 624-627.
[4] SHI SY, LIU ZX, ZHAO HY, et al.Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 2)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2022, 43(11): 1835-1841.
[5] SHI SY, LIU ZX, ZHAO HY, et al.Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 1)[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2022, 43(11): 1828-1834.
[6] Center For Drug Evaluation, National Medical Products Administration. Guidelines (Trial Implementation) for Real World Data Used to Generate Real World Evidence[EB/OL](2021-04-13)[2024-02-15]. https://www.cde.org.cn/main/news/viewInfoCommon/ 2a1c437ed54e7b838a7e86f4ac21c539.
[7] BASCH E, SCHRAG D.The evolving uses of“real-world”data[J]. JAMA, 2019, 321(14): 1359-1360.
[8] LI G, YANG ZR, ZHAO HY, et al.External control in studies using real-world data: current situation and exemplar[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2021(11): 56-61.
[9] QIN XN, CHEN WS, SHAO H, et al.Application and research method of real world research in the medical field[J]. Progress in Pharmaceutical Sciences(药学进展), 2021, 45(7): 512-523.
[10] FLYNN R, PLUESCHKE K, QUINTEN C, et al.Marketing authorization applications made to the European medicines agency in 2018-2019: what was the contribution of real-world evidence?[J]. Clin Pharmacol Ther, 2022, 111(1): 90-97.
[11] Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff[EB/OL]. (2017-08-31)[2023-12-10]. https://www.fda.gov/media/99447/download.
[12] FDA. Framework for FDA’s real-world evidence program [EB/OL]. (2018-12-31)[2023-12-10]. https://www.fda.gov/media/120060/download.
[13] FDA. Use of Electronic Health Record Data in Clinical Investigations[EB/OL]. (2018-12-06)[2023-12-10]. https://www.fda.gov/media/119659/download.
[14] FDA. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products[EB/OL]. (2022-09-08)[2023-12-10]. https://www.fda.gov/media/124795/download.
[15] NMPA. Guiding principles of real-world evidence supporting drug development and evaluation (trial implementation) [EB/OL]. (2020-01-03)[2023-12-10]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200107151901190.html.
[16] NMPA. Technical guiding principles of real-world study supporting the development and evaluation of children’s drugs (trial implementation)[EB/OL] (2020-08-27)[2023-12-10]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html.
[17] LI H, PAN YG, WANG L.Bibliometrix: a new bibliometrics analysis software[J]. Journal of Academic Library and Information Science(大学图书情报学刊), 2018, 36(4): 93-104.
[18] NMPA.Good Clinical Practice[EB/OL] (2020-04-23)[2023-12-10]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200426162401243.html.
[19] HUISMAN MV, TEUTSCH C, LU S, et al.Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from phase III of the GLORIA-AF registry[J]. Clin Res Cardiol, 2022, 111(5): 548-559.
[20] LAKKIREDDY D, REDDY Y M, DI BIASE L, et al.Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry[J]. Journal of the American College of Cardiology, 2014, 63(10): 982-988.
[21] LAKKIREDDY D, REDDY Y M, DI BIASE L, et al.Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry[J]. Journal of the American College of Cardiology, 2012, 59(13): 1168-1174.
[22] LARSEN TB, SKJØTH F, NIELSEN PB, et al. Comparative effectiveness and safety of non-Vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study[J]. BMJ, 2016, 353: i3189.
[23] Society of Cancer Big Data and Real World Study of China Anti-Cancer Association. Chinese expert consensus on big data and real world study in cancer research (2022 edition)[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2022(12): 1330-1343.
[24] BAUMFELD AE, REYNOLDS R, CAUBEL P, et al.Trial designs using real-world data: the changing landscape of the regulatory approval process[J]. Pharmacoepidemiol Drug Saf, 2020, 29(10): 1201-1212.
[25] SANTORO F, NúñEZ-GIL IJ, VITALE E, et al. Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: a propensity score-matched cohort analysis of the HOPE-COVID-19 Registry[J]. J Am Heart Assoc, 2022, 11(13).
[26] SANTORO F, NUñEZ-GIL IJ, VITALE E, et al. Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry[J]. Heart, 2022, 108(2): 130-136.
[27] ALRASHED A, CAHUSAC P, MOHZARI YA, et al.A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data[J]. Front Cardiovasc Med, 2022, 9: 978420.
[28] REDDY P K, PATIL S, KHOBRAGADE A, et al.Evaluation of the safety and efficacy of favipiravir in adult indian patients with mild-to-moderate COVID-19 in a real-world setting[J]. Int J Gen Med, 2022, 15: 4551-4563.
[29] ZHONG L, LI YS, XIONG L, et al.Small molecules in targeted cancer therapy: advances, challenges, and future perspectives[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 201.
[30] BEDARD PL, HYMAN DM, DAVIDS MS, et al.Small molecules, big impact: 20 years of targeted therapy in oncology[J]. Lancet, 2020, 395(10229): 1078-1088.
[31] Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association, Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association, Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. China Oncology(中国癌症杂志), 2024, 34(1): 104-134.
[32] Chinese Ecoi, Western Medicine C.Expert consensus on the diagnosis and treatment of integrated Chinese and Western medicine for myelosuppression caused by antitumor drugs[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2021, 26(11): 1020-1027.
[33] HUANG CX, ZHANG S, HUANG DJ, et al.Current knavledge and management recommendations of atrial fibrillation: 2018[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2018, 32(4): 315-368.
[34] YANG J, TANG YD.Application of novel oral anticoagulants in cardiovascular diseases[J]. Molecular Cardiology of China(中国分子心脏病学杂志), 2021, 21(4): 4142-4146.
[35] FLEURENCE RL, BLAKE K, SHUREN J.The future of registries in the era of real-world evidence for medical devices[J]. JAMA Cardiol, 2019, 4(3): 197-198.
[36] PENBERTHY LT, RIVERA DR, LUND JL, et al.An overview of real-world data sources for oncology and considerations for research[J]. CA Cancer J Clin, 2022, 72(3): 287-300.
[37] WENG HF, ZHANG YF, LIU B.Cross-border health services and digitalization in Europe[J]. Chinese Health Resources(中国卫生资源), 2021, 24(6): 820-825.
[38] JIA YL, YAO MH, LIU YM, et al.Exploring the patterns of real-world data governance in the context of special healthcare policy[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2021, 21(12): 1373-1380.
[39] JIN FF, YAO C, MA J, et al.Explore efficient and feasible clinical real world data collection mode in Hainan Boao Lecheng International Medical Tourism Pilot Zone[J]. China Food Drug Administration(中国食品药品监管), 2020(11): 21-31.

多中心真实世界数据评价药品安全性研究进展

Evaluation of drug safety with multicenter real-world data

PDF (PC)

增强发表(附录)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	阿拉腾花, 高磊, 张晓朦, 张冰. 基于蒙医药学古籍文献探析蒙药药物警戒科学内涵[J]. 中国药物警戒, 2024, 21(6): 677-682.
[2]	王书波, 焦婷婷, 董洪亮, 王百聆, 李辉. 基于真实世界数据研究注射用伏立康唑致急性肾损伤的危险因素建立预测模型及验证[J]. 中国药物警戒, 2024, 21(5): 567-571.
[3]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[4]	王丹丹, 王莹, 姚令文, 刘芫汐, 金红宇, 马双成. 顶空-气相色谱法测定到手香提取物11种溶剂残留量[J]. 中国药物警戒, 2024, 21(3): 295-299.
[5]	马美英, 赵晓佩, 张梦瑶, 胡一琳. 我国药品追溯码编码制度研究探讨[J]. 中国药物警戒, 2024, 21(2): 167-172.
[6]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[7]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[8]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[9]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[10]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[11]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[12]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[13]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[14]	徐帅, 陈恂, 卞昊宇, 赵玉清, 张立平. 基于CiteSpace知识图谱的中草药致肝损伤研究热点与趋势分析[J]. 中国药物警戒, 2023, 20(5): 560-567.
[15]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.